Stengone Carmine N. — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Stengone Carmine N. has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $320K.

Profile

Stengone Carmine N.

Carmine N. Stengone is the Chief Executive Officer and President of Contineum Therapeutics, Inc., and serves as a director, per the latest SEC filing dated 2026-01-30. He leads the clinical-stage biopharmaceutical company, which focuses on oral small-molecule therapies, including PIPE-791 (LPA1R inhibitor for IPF) and PIPE-307 (M1R inhibitor for depression and RRMS). Contineum Therapeutics has about 41 employees.

RoleCEO and President, Director
Notability40/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-07-08CTNMContineum Therapeutics, Inc.S — Open-market sale2.5K$16.00$40K
2026-07-08CTNMContineum Therapeutics, Inc.M — Option exercise2.5K$1.01$3K
2026-07-01CTNMContineum Therapeutics, Inc.S — Open-market sale10.0K$16.01$160K
2026-07-01CTNMContineum Therapeutics, Inc.M — Option exercise2.5K$1.26$3K
2026-07-01CTNMContineum Therapeutics, Inc.M — Option exercise7.5K$1.01$8K
2026-02-26CTNMContineum Therapeutics, Inc.S — Open-market sale [10b5-1]2.7K$16.02$43K
2026-02-26CTNMContineum Therapeutics, Inc.M — Option exercise [10b5-1]2.7K$1.26$3K
2026-02-26CTNMContineum Therapeutics, Inc.S — Open-market sale [10b5-1]4.4K$16.02$70K
2026-02-26CTNMContineum Therapeutics, Inc.M — Option exercise [10b5-1]4.4K$1.26$6K
2026-02-13CTNMContineum Therapeutics, Inc.S — Open-market sale [10b5-1]400$16.00$6K
2026-02-13CTNMContineum Therapeutics, Inc.M — Option exercise [10b5-1]400$1.26$504

Companies — Last 90 Days

Frequently Asked Questions

Who is Stengone Carmine N.?

Carmine N. Stengone is the Chief Executive Officer and President of Contineum Therapeutics, Inc., and serves as a director, per the latest SEC filing dated 2026-01-30. He leads the clinical-stage biopharmaceutical company, which focuses on oral small-molecule therapies, including PIPE-791 (LPA1R inhibitor for IPF) and PIPE-307 (M1R inhibitor for depression and RRMS). Contineum …

How many SEC Form 4 filings has Stengone Carmine N. submitted recently?

3 primary Form 4 filings in the last 90 days, covering 2 companies.

Has Stengone Carmine N. been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 5 open-market sales ($320K) across all tracked filings.

Where can I see all of Stengone Carmine N.'s SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Stengone Carmine N. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.